New thiosemicarbazones: synthesis, structural characterization, in vitro, and in silico evaluation of antiproliferative effects
Yazarlar (6)
Öğr. Gör. Hanife ARDAHANLI Kafkas Üniversitesi, Türkiye
Arş. Gör. Yavuz Derin Türkiye
Raşit Fikret Yılmaz
Türkiye
Türkiye
Haşim Gül
Doç. Dr. Mustafa SERTÇELİK Kafkas Üniversitesi, Türkiye
Prof. Dr. Ahmet Tutar Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Future Medicinal Chemistry (Q2) | ||
| Dergi ISSN | 1756-8919 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | Türkçe | Basım Tarihi | 10-2025 |
| Cilt / Sayı / Sayfa | – / 0 / – | DOI | 10.1080/17568919.2025.2570969 |
| Makale Linki | https://doi.org/10.1080/17568919.2025.2570969 | ||
| UAK Araştırma Alanları |
Fen Bilimleri ve Matematik
|
||
| Özet |
| AimsTo design, synthesize, and characterize N-(4-bromophenyl)-2-(substituted fluorobenzylidene)hydrazine-1-carbothioamides (II–IV) and evaluate their in vitro cytotoxicity against DLD-1 and MDA-MB-231 cells, supported by molecular docking.Materials & methodsCompounds were obtained by condensations of substituted fluorobenzaldehydes with N-(4-bromophenyl)hydrazinecarbothioamide and characterized by NMR, FTIR, and MS. DLD-1 and MDA-MB-231 cells were exposed to 50–1600 µg/mL for 24 h; viability was measured using a commercial colorimetric assay. Statistics used one-way ANOVA with post hoc tests. Blind docking was performed with CB-Dock2 and interactions inspected in Discovery Studio.ResultsAll compounds decreased viability in a concentration-dependent manner. In MDA-MB-231, Compounds I, II, and IV showed significant effects (ANOVA p < 0.001). In DLD-1, Compound IV … |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 1 |